Printable Biography of Edward Lanphier

In 1981, Mr. Lanphier published the first commercial analysis of the then nascent biotechnology industry. He authored the first "Genetic Engineering Industry Directory" as well as studies detailing the potential commercial significance of this emerging science including reports entitled Advances in Biotechnology Commercialization and Monoclonal Antibody Market Opportunities. In 1982 he joined Eli Lilly & Co. in the Strategic Business Planning group responsible for biotechnology product acquisitions. This began a career that has seen Edward Lanphier start, build or take public several leading biotechnology companies including Celtrix Pharmaceuticals, Somatix Therapy Corporation and Sangamo BioSciences.

As a biotechnology industry veteran, Edward Lanphier will share his perspectives on the role of biotechnology (and other emerging technologies such as the sequencing of the human genome, bioinformatics, gene therapy, and genetically modified transgenic plants) in our society and our economy. Additionally he can address the importance of research and development in the pharmaceutical and agricultural industries and the need for public policies to support these efforts.

Edward Lanphier is a frequent speaker at a wide range of biotechnology industry conferences. In the past two years he has made presentations at some of the countries premier financial conferences including the Hambrecht & Quist Health Care Conference; the BancBoston Robertson, Stephens Medical Conference; and the U.S. Bancorp Piper Jaffray Medical Technologies Conference.

Additionally Edward Lanphier has given detailed commercial presentations on gene therapy, regulation of gene expression, development of transgenic plants, novel anti-viral therapeutics, and DNA diagnostics/pharmacogenomics.

Edward Lanphier is the founder, President and Chief Executive Officer of Sangamo BioSciences, Inc. Sangamo is a publicly held biotechnology company (NASDAQ: SGMO) focused on the development of novel transcription factors for the regulation of human, plant and microbial genes. The company has signed collaborative research agreements with Pfizer, SmithKline Beecham, Millennium Pharmaceuticals, Zeneca, Berlex Biosciences, Bayer AG, GlaxoWellcome, DuPont Pharmaceuticals, Japan Tobacco, Hoffmann-LaRoche and Genset.

Edward Lanphier has twenty years of experience in the pharmaceutical and biotechnology industry. From 1992 to 1997, he was executive vice president, commercial development and chief financial officer (1996-97) at Somatix Therapy Corporation, a leading gene therapy company. Prior to Somatix, Mr. Lanphier was president and chief executive officer of BioGrowth, Inc., which merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. Mr. Lanphier was also the vice president of corporate development at Synergen, Inc. and before joining Synergen in 1984, he was with Eli Lilly and Company in Strategic Business Planning - Biotechnology.

Mr. Lanphier is a member of the Biotechnology Industry Organization (BIO) board of directors.